Get started
Author

Darren Foard

Observed names: D Foard, D. Foard, DM Foard, Foard D, Foard, D, Foard, DM, Foard, Darren
OpenAlex ID: A5008614232
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
2013 · Ashutosh D. Wechalekar, Stefan O. Schonland, et al. · Blood · 529
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
2012 · Christopher P. Venner, Thirusha Lane, et al. · Blood · 282
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
2019 · Richa Manwani, Oliver Cohen, et al. · Blood · 194
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis
2021 · Oliver C Cohen, Andreia Ismael, et al. · European Heart Journal · 113
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
2014 · C P Venner, J D Gillmore, et al. · Leukemia · 99
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
2022 · Eli Muchtar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 94
PDF
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis
2018 · Richa Manwani, Darren Foard, et al. · Haematologica · 65
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens
2014 · Shameem Mahmood, Christopher P. Venner, et al. · British Journal of Haematology · 53
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
2024 · Joshua Bomsztyk, Sriram Ravichandran, et al. · Blood · 38
PDF
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor
2017 · Tamer Rezk, Helen J. Lachmann, et al. · Kidney International · 36
PDF
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
2021 · Sriram Ravichandran, Oliver C. Cohen, et al. · Blood Cancer Journal · 34
PDF
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine
2018 · Richa Manwani, Sajitha Sachchithanantham, et al. · Blood · 34
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis
2024 · Eli Muchtar, Brendan Wisniowski, et al. · JAMA Oncology · 31
PDF
Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting
2014 · C. P. Venner, J. D. Gillmore, et al. · Haematologica · 24
PDF
Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers
2019 · Tamer Rezk, Helen J. Lachmann, et al. · British Journal of Haematology · 22
PDF
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis
2015 · S. Sachchithanantham, M. Offer, et al. · Haematologica · 21
PDF
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis
2022 · Oliver C Cohen, Ananth Sathyanath, et al. · Heart · 17
PDF
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients
2024 · Jahanzaib Khwaja, Sriram Ravichandran, et al. · Haematologica · 14
PDF
Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years
2013 · Shameem Mahmood, Sajitha Sachchithanantham, et al. · Blood · 14
European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease
2011 · Ashutosh Wechalekar, Stefan O Schonland, et al. · Blood · 14
ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis
2011 · Thirusha Lane, Lisa Rannigan, et al. · Blood · 13
Comparison of Free Light Chain Assays
2016 · Shameem Mahmood, Nancy L. Wassef, et al. · American Journal of Clinical Pathology · 12
Graded Renal Response Criteria for Light Chain (AL) Amyloidosis
2021 · Eli Muchtar, Brendan Wisniowski, et al. · Blood · 10
A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort
2014 · Ashutosh Wechalekar, Carol Whelan, et al. · Blood · 10
Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival
2021 · Eli Muchtar, Angela Dispenzieri, et al. · Blood · 8
Works count: 81
Citation count: 1,888
H-index: 17
I10-index: 24
Year
Topic
Type